Chinese(GB)     
Contact CFDA
   
HOME ABOUT CFDA WHAT'S NEW LAWS & REGULATIONS REGULATORY GUIDE DATA SEARCH SITE MAP
  Search      
Home >> What's New  
What's New
2017's The Senior Officials & First Working Group Meeting of the China Food and Drug Administration and the Hongkong Food and Health Bureau was held in Shenzhen
2017-11-30

In order to implement the consensus reached after the meeting of Bi Jingquan,Minister of China Food and Drug Administration (CFDA) and Secretary for Hongkong Food and Health Bureau,Professor Sophia CHAN,JP at the end of August this year,on November 24,2017,the Senior Officials & First Working Group Meeting of the China Food and Drug Administration with the Hongkong Food and Health Bureau was held in Shenzhen.Wu Zhen,CFDA’s Vice Minister and Under Secretary for Hongkong Food and Health Bureau,Dr CHUI Tak-yi,JP,attended the meeting and spoke.
Wu Zhen pointed out that in 2014,the two sides signed the “cooperation agreement on food and drug regulation” and formally established a cooperative mechanism.The CFDA has authorized 3 Hongkong clinical institutions to take the drug clinical trials approved by the CFDA,cooperate with Hongkong to implement the registration system of Chinese patent medicines,and help Hongkong formulate the standard of Chinese herbal medicines,recommends that Hong Kong experts serve as members of the new national pharmacopoeia commission,and carry out personnel exchanges and training,cooperation between the two sides has been steadily advancing.He also emphasized that the CFDA will conscientiously carry out the Nineteen Spirits and General Secretary Xi Jinping's important instructions on promoting the prosperity and development of Hongkong,and continue to support the two sides' exchanges and cooperation in the field of food and drug supervision.Under the framework of the cooperation agreement,a senior officials meeting is held on a regular basis.Relying on the established Good Manufacture Practice(GMP),we should check the working group,the clinical trial group and the medical device management team,so as to enhance communication and share experiences.The CFDA will also continue to support the preparatory work of the Hongkong Specimen Museum.
Dr CHUI Tak-yi,JP thanked the CFDA for its support in the promotion and development of traditional Chinese medicine in Hongkong.We hope to effectively enhance the supervision through three working groups,including GMP inspection,drug clinical management and medical device management.
This meeting was chaired by Yuan Lin,Director of CFDA’s Hong Kong,Macao and Taiwan Office.The three working groups exchanged and studied the next work of the two sides respectively.

HOME | ABOUT CFDA | WHAT'S NEW | LAWS AND REGULATIONS | REGULATORY GUIDE | DATA SEARCH
| SITE MAP |
© CFDA
Constructed and Maintained by the Information Center of CFDA